Cellbion Co., Ltd. is a South Korea-based biopharmaceutical company focused on the discovery, development, and commercialization of precision theranostic radiopharmaceuticals for oncology indications. Founded in 2010 and headquartered in Seoul, South Korea, the company develops targeted radioligand therapies, antibody-radionuclide conjugates, and complementary molecular diagnostic imaging agents leveraging proprietary hydrophilic linker and radiolabeling technologies. The company structures its operations into two primary business segments: Therapeutic Radiopharmaceuticals and Diagnostic Radiopharmaceuticals. Cellbion's core product portfolio and pipeline include 177Lu-DGUL (lutetium (177Lu) pocuvotide satetraxetan), a clinical-stage prostate-specific membrane antigen (PSMA)-targeted therapeutic radioligand designed for the treatment of metastatic castration-resistant prostate cancer (mCRPC); 68Ga-NGUL, a gallium-68-labeled companion positron emission tomography (PET/CT) diagnostic imaging agent engineered for high-affinity PSMA tumor detection with reduced non-target organ uptake; 68Ga-FAP and 225Ac-FAP, preclinical diagnostic imaging and targeted alpha therapy candidates directed against fibroblast activation protein in solid tumors; and novel antibody-radionuclide conjugates utilizing actinium-225 and lutetium-177 radionuclides for refractory cancer targets. The company maintains Good Manufacturing Practice (GMP)-certified radiopharmaceutical production and quality control facilities at the Seoul National University Hospital Cancer Research Institute and a specialized research center in Bundang, serving clinical research institutions, hospitals, and oncology care providers. In October 2024, Cellbion completed its initial public offering and listed its common shares on the KOSDAQ market under ticker symbol 308430. Recent corporate and clinical developments include submitting an application for conditional marketing authorization in South Korea for lead drug 177Lu-DGUL following the conclusion of Phase 2 clinical trials; conducting the collaborative IGNITE trial evaluating 177Lu-DGUL in combination with the immune checkpoint inhibitor pembrolizumab (Keytruda); securing global clinical supply and CDMO manufacturing arrangements with Canada-based Centre for Probe Development and Commercialization (CPDC) and AtomVie Global Radiopharma; and entering into a strategic memorandum of understanding with Ahn-Gook Pharmaceutical Co., Ltd. in September 2026 to jointly research, discover, and develop next-generation targeted radiopharmaceutical therapies.